Cabergoline for postpartum lactation suppression: Effect on blood pressure and pulse

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Maternal Health

Background:

• Postpartum care requires monitoring hemodynamic stability.
• Lactation suppression is common, with various medications available.
• Understanding medication side effects is crucial for maternal safety.

Purpose of the Study:

• To assess the immediate postpartum effects of cabergoline on maternal blood pressure and pulse.
• To evaluate the safety and hemodynamic impact of cabergoline in non-breastfeeding postpartum women.

Main Methods:

• Retrospective cohort study of 224 non-breastfeeding postpartum women.
• Compared women receiving 1mg cabergoline within 48 hours postpartum to unexposed women.
• Monitored systolic/diastolic blood pressure and pulse at 4-hour intervals up to 24 hours post-administration.

Main Results:

• Cabergoline-exposed women exhibited lower mean systolic blood pressure throughout the study period.
• A maximum systolic blood pressure decrease of -10.88 mmHg was observed between 20-24 hours.
• Diastolic blood pressure showed a significant decrease (-8.15 mmHg) only at the >20-24 hour interval; no pulse changes were noted.
• Cabergoline was well tolerated with no adverse effects.

Conclusions:

• Cabergoline demonstrates minimal clinically significant hemodynamic effects in normotensive postpartum women.
• The medication is well-tolerated, supporting its use for lactation suppression.